RxDoctor Payments Data

Stephanie Schmidt, APRN

Family · Milford, OHNPI 1346997947

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 90 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$333
  • Novo Nordisk$271
  • Lilly USA, LLC$252
  • Astellas Pharma US Inc$120
  • Biohaven Pharmaceutical Holding Company Ltd.$92
  • Amgen$83
  • plus $412 from 12 others

What the payments were for

  • Food & beverage$1,49095%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$49,818
Medicare patients
234
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$126,710
JardianceEmpagliflozin58$85,021
EliquisApixaban60$77,297
MounjaroTirzepatide50$69,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$53,098
XareltoRivaroxaban41$37,026
TrulicityDulaglutide25$36,997
FarxigaDapagliflozin Propanediol18$26,845
RybelsusSemaglutide11$23,045
Spiriva RespimatTiotropium Bromide26$21,398
JanuviaSitagliptin Phosphate15$20,660
MyrbetriqMirabegron11$6,871
SymbicortBudesonide/Formoterol Fumarate12$6,419
Breo ElliptaFluticasone/Vilanterol14$5,513
Albuterol Sulfate HfaAlbuterol Sulfate178$4,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$271$149,755118 claims
Lilly USA, LLCMounjaro, Trulicity$252$106,75675 claims
Boehringer IngelheimJardiance, Spiriva Respimat$54$106,41984 claims
PfizerEliquis, Premarin$29$81,77571 claims
GSKTrelegy Ellipta, Breo Ellipta$12$58,61273 claims
Johnson & JohnsonXarelto$17$37,02641 claims
AstraZenecaFarxiga, Symbicort$40$33,26530 claims
Astellas Pharma US IncMyrbetriq$120$6,87111 claims
AbbVieSynthroid$333$1,79227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Milford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →